632 related articles for article (PubMed ID: 16820548)
1. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
Tonstad S; Tønnesen P; Hajek P; Williams KE; Billing CB; Reeves KR;
JAMA; 2006 Jul; 296(1):64-71. PubMed ID: 16820548
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
[TBL] [Abstract][Full Text] [Related]
3. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.
Koegelenberg CF; Noor F; Bateman ED; van Zyl-Smit RN; Bruning A; O'Brien JA; Smith C; Abdool-Gaffar MS; Emanuel S; Esterhuizen TM; Irusen EM
JAMA; 2014 Jul; 312(2):155-61. PubMed ID: 25005652
[TBL] [Abstract][Full Text] [Related]
5. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
Tonstad S
J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
[TBL] [Abstract][Full Text] [Related]
6. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.
Bolliger CT; Issa JS; Posadas-Valay R; Safwat T; Abreu P; Correia EA; Park PW; Chopra P
Clin Ther; 2011 Apr; 33(4):465-77. PubMed ID: 21635992
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
Nakamura M; Oshima A; Fujimoto Y; Maruyama N; Ishibashi T; Reeves KR
Clin Ther; 2007 Jun; 29(6):1040-56. PubMed ID: 17692720
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
Tsai ST; Cho HJ; Cheng HS; Kim CH; Hsueh KC; Billing CB; Williams KE
Clin Ther; 2007 Jun; 29(6):1027-39. PubMed ID: 17692719
[TBL] [Abstract][Full Text] [Related]
9. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.
Evins AE; Cather C; Pratt SA; Pachas GN; Hoeppner SS; Goff DC; Achtyes ED; Ayer D; Schoenfeld DA
JAMA; 2014 Jan; 311(2):145-54. PubMed ID: 24399553
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
[TBL] [Abstract][Full Text] [Related]
11. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.
Ebbert JO; Hughes JR; West RJ; Rennard SI; Russ C; McRae TD; Treadow J; Yu CR; Dutro MP; Park PW
JAMA; 2015 Feb; 313(7):687-94. PubMed ID: 25688780
[TBL] [Abstract][Full Text] [Related]
12. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.
Williams JM; Anthenelli RM; Morris CD; Treadow J; Thompson JR; Yunis C; George TP
J Clin Psychiatry; 2012 May; 73(5):654-60. PubMed ID: 22697191
[TBL] [Abstract][Full Text] [Related]
14. Varenicline for smoking cessation: a placebo-controlled, randomized study.
Wang C; Xiao D; Chan KP; Pothirat C; Garza D; Davies S
Respirology; 2009 Apr; 14(3):384-92. PubMed ID: 19192221
[TBL] [Abstract][Full Text] [Related]
15. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial.
Anthenelli RM; Morris C; Ramey TS; Dubrava SJ; Tsilkos K; Russ C; Yunis C
Ann Intern Med; 2013 Sep; 159(6):390-400. PubMed ID: 24042367
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial.
Hoogsteder PH; Kotz D; van Spiegel PI; Viechtbauer W; van Schayck OC
Addiction; 2014 Aug; 109(8):1252-9. PubMed ID: 24894625
[TBL] [Abstract][Full Text] [Related]
17. Varenicline: a first-line treatment option for smoking cessation.
Garrison GD; Dugan SE
Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
[TBL] [Abstract][Full Text] [Related]
18. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial.
Fagerström K; Gilljam H; Metcalfe M; Tonstad S; Messig M
BMJ; 2010 Dec; 341():c6549. PubMed ID: 21134997
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial.
Hoogsteder PH; Kotz D; van Spiegel PI; Viechtbauer W; Brauer R; Kessler PD; Kalnik MW; Fahim RE; van Schayck OC
BMC Public Health; 2012 Dec; 12():1052. PubMed ID: 23216646
[TBL] [Abstract][Full Text] [Related]
20. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
Lam S; Patel PN
Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
